708 related articles for article (PubMed ID: 32660841)
1. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
3. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
4. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
[TBL] [Abstract][Full Text] [Related]
5. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
8. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
9. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
10. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
12. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
Mun EJ; Green P; Berry K; Ioannou GN
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):47-52. PubMed ID: 30142097
[TBL] [Abstract][Full Text] [Related]
13. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
14. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
[TBL] [Abstract][Full Text] [Related]
16. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Kaneoka Y; Maeda A; Akita T; Tanaka J
Aliment Pharmacol Ther; 2018 Sep; 48(6):664-670. PubMed ID: 30047149
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
[TBL] [Abstract][Full Text] [Related]
18. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
